Clinical Trial Update: Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years [Phase 4]

View source ↗

Summary

A Phase 4 pharmacokinetic study of DYANAVEL XR extended-release amphetamine in children aged 4 to 5 years with ADHD has been completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Dyanavel XR (amphetamine (extended-release))

Snippet

Sponsor: Tris Pharma, Inc. | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: COMPLETED | Results posted: 2019-06-25